Anemia and Erythrocytosis After Kidney Transplantation: A 5-Year Graft Function and Survival Analysis

Kolonko, Aureliusz; Pinocy-Mańdok, J.; Kocierz, Magdalena; Kujawa-Szewieczek, Agata; Chudek, Jerzy; Małyszko, Jolanta; Myśliwiec, Michał; Wiȩcek, Andrzej

doi:10.1016/j.transproceed.2009.07.090

Cited by 32 publications

(30 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other reports confirmed an association between allograft loss and PTA diagnosed at 3 months [59], 12 months [22] or thereafter [10,58,60]. In a Polish study, persistent and late‐onset PTA was associated with the increased risk of graft loss [23]. Anemia was associated with poorer graft survival also in recipients of living donor organs [62].…”

Section: Post‐transplant Anemia (Pta)mentioning

confidence: 82%

“…In a recent study by Kolonko et al. [23] PTE did not affect the risk of graft loss or patient death. Kiberd [2] found that patients with erythrocytosis had superior overall survival but a trend for worse death censored graft loss.…”

Section: Post‐transplant Erythrocytosis (Pte)mentioning

confidence: 91%

“…Serum creatinine at 6 months is an independent predictor for anemia at 1 year [22]. Patients with eGFR <41 ml/min/1.73 m 2 at 12 months post transplant were more likely to have persistent anemia [23].…”

Section: Post‐transplant Anemia (Pta)mentioning

confidence: 99%

See 2 more Smart Citations

Anemia and Erythrocytosis in patients after kidney transplantation

Małyszko¹,

Oberbauer²,

Watschinger³

2012

Transplant International

View full text Add to dashboard Cite

Summary Anemia is a highly prevalent disorder in recipients of renal allografts. Despite its frequent occurrence, there is still uncertainty with regard to treatment targets and treatment options. This includes questions on appropriate iron management, the choice and dosage of erythropoietin stimulating agents, criteria for the timing of treatment initiation and the targeted hemoglobin values. The review summarizes available data on recent therapeutic strategies for post‐trasnplant anemia, as well as for post transplant erythrocytosis, another hematological disorder, that has decreased in recent years.

show abstract

Section: Post‐transplant Anemia (Pta)mentioning

confidence: 82%

Section: Post‐transplant Erythrocytosis (Pte)mentioning

confidence: 91%

See 1 more Smart Citation

Anemia and Erythrocytosis in patients after kidney transplantation

Małyszko¹,

Oberbauer²,

Watschinger³

2012

Transplant International

View full text Add to dashboard Cite

show abstract

“…In the largest series to date, an analysis of 5,834 kidney transplant recipients at 10 European outpatient transplant clinics detected anemia in 42% of patients based on the American Society of Transplantation anemia guidelines (Hb ≤ 13.0 g/dL in males and ≤ 12.0 g/dL in females) [6]. Using the same thresholds, large single-center cohort studies have found that 30–35% of kidney transplant patients have anemia [7–9]. In nontransplant CKD populations, anemia is predictive of cardiovascular events [10], mortality [11, 12], and diminished quality of life [13].…”

Section: Introductionmentioning

confidence: 99%

“…In nontransplant CKD populations, anemia is predictive of cardiovascular events [10], mortality [11, 12], and diminished quality of life [13]. Posttransplant anemia is significantly associated with increased death-censored [14, 15] and all-cause [9, 16, 17] graft loss, probably cardiovascular events [18] and possibly mortality [16–19], although causative relationships are not certain and anemia may be a marker for other pathologic processes.…”

Section: Introductionmentioning

confidence: 99%

Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study

Budde

Rath

Kliem³

2014

Journal of Transplantation

View full text Add to dashboard Cite

In a multicenter, prospective, observational study of 279 kidney transplant recipients with anemia, the efficacy and safety of once-monthly continuous erythropoietin receptor activator (C.E.R.A.) were assessed to a maximum of 15 months. The main efficacy variable was the proportion of patients achieving a hemoglobin level of 11-12 g/dL at each of visits between months 7 and 9. At study entry, 224 patients (80.3%) were receiving erythropoiesis stimulating agent (ESA) therapy including darbepoetin alfa (98), epoetin beta (61), and C.E.R.A. (45). The mean (SD) time between C.E.R.A. applications was 34.0 (11.9) days. Among 193 patients for whom efficacy data were available, mean (SD) hemoglobin was 11.1 (0.99) g/dL at study entry, 11.5 (1.1) g/dL at month 7, 11.6 (1.3) g/dL at month 9, and 11.4 (1.1) g/dL at month 15. During months 7–9, 20.7% of patients had all hemoglobin values within the range 11-12 g/dL and 64.8% were within 10–13 g/dL. Seven patients (2.5%) discontinued C.E.R.A. due to adverse events or serious adverse events. In this observational trial under real-life conditions, once-monthly C.E.R.A. therapy achieved stable hemoglobin levels in stable kidney transplant recipients with good tolerability, and with no requirement for any dose change in 43% of patients.

show abstract

Post-Transplant Anemia

Mandayam

2017

Management of Anemia

View full text Add to dashboard Cite

Anemia and Erythrocytosis After Kidney Transplantation: A 5-Year Graft Function and Survival Analysis

Cited by 32 publications

References 36 publications

Anemia and Erythrocytosis in patients after kidney transplantation

Anemia and Erythrocytosis in patients after kidney transplantation

Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study

Post-Transplant Anemia

Contact Info

Product

Resources

About